Get the Stockscreener App
0.94
17.93%
0.1429
After Hours:
.93
-0.010
-1.06%
Allarity Therapeutics Inc stock is traded at $0.94, with a volume of 1.89M.
It is up +17.93% in the last 24 hours and up +1.29% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
See More
Previous Close:
$0.7971
Open:
$0.8
24h Volume:
1.89M
Relative Volume:
0.88
Market Cap:
$12.20M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00456
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
+29.64%
1M Performance:
+1.29%
6M Performance:
-45.03%
1Y Performance:
-37.33%
1-Day Range:
$0.7799
$0.95
1-Week Range:
$0.6585
$0.95
52-Week Range:
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.94 | 12.20M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Allarity Therapeutics Restructures Board of Directors - TipRanks
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com
Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Allarity Therapeutics, Inc. SEC 10-K Report - TradingView
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan
Allarity Therapeutics Inc. (ALLR) reports earnings - qz.com
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter
Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World
Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia
Allarity Therapeutics probes potential stock manipulation - Investing.com
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan
Investigation announced for Long-Term Investors in shares - openPR.com
ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times
Allarity reports promising ovarian cancer trial results - Investing.com
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian
Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com
Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia
SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - Bloomberg Law News
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire
Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener
Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com
Allarity Therapeutics Announces Final Settlement with SEC Over Previous Disclosures Regarding NDA for Dovitinib - Nasdaq
Allarity Settles SEC Probe: $2.5M Fine Won't Impact Clinical Trials or 2026 Outlook - StockTitan
SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval - Law360
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib and Temozolomide for Recurrent Small Cell Lung Cancer - Nasdaq
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - The Manila Times
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):